KR101586273B1 - 호흡기 질환 치료용 정량분무식 흡입제의 제조 방법 - Google Patents

호흡기 질환 치료용 정량분무식 흡입제의 제조 방법 Download PDF

Info

Publication number
KR101586273B1
KR101586273B1 KR1020147004283A KR20147004283A KR101586273B1 KR 101586273 B1 KR101586273 B1 KR 101586273B1 KR 1020147004283 A KR1020147004283 A KR 1020147004283A KR 20147004283 A KR20147004283 A KR 20147004283A KR 101586273 B1 KR101586273 B1 KR 101586273B1
Authority
KR
South Korea
Prior art keywords
hfa
total weight
mixture
alcohol
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147004283A
Other languages
English (en)
Korean (ko)
Other versions
KR20140042898A (ko
Inventor
웨이-슈 우
옌-친 챠오
Original Assignee
인텍 바이오팜 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인텍 바이오팜 엘티디. filed Critical 인텍 바이오팜 엘티디.
Publication of KR20140042898A publication Critical patent/KR20140042898A/ko
Application granted granted Critical
Publication of KR101586273B1 publication Critical patent/KR101586273B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147004283A 2011-03-17 2012-02-14 호흡기 질환 치료용 정량분무식 흡입제의 제조 방법 Expired - Fee Related KR101586273B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TW100109223A TWI399202B (zh) 2011-03-17 2011-03-17 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
CN201110239124.1A CN102670505B (zh) 2011-03-17 2011-08-19 制备用于治疗呼吸道疾病的定量喷雾吸入剂的工艺方法
CN201110239124.1 2011-08-19
PCT/CN2012/071129 WO2013026269A1 (zh) 2011-03-17 2012-02-14 制备用于治疗呼吸道疾病的定量喷雾吸入剂的工艺方法

Publications (2)

Publication Number Publication Date
KR20140042898A KR20140042898A (ko) 2014-04-07
KR101586273B1 true KR101586273B1 (ko) 2016-01-18

Family

ID=54253387

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147004283A Expired - Fee Related KR101586273B1 (ko) 2011-03-17 2012-02-14 호흡기 질환 치료용 정량분무식 흡입제의 제조 방법

Country Status (10)

Country Link
EP (1) EP2749275A4 (https=)
JP (1) JP5938476B2 (https=)
KR (1) KR101586273B1 (https=)
CN (1) CN102670505B (https=)
AU (1) AU2012300082B2 (https=)
CA (1) CA2845258C (https=)
RU (1) RU2582218C2 (https=)
SG (1) SG2014011597A (https=)
TW (1) TWI399202B (https=)
WO (1) WO2013026269A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6739343B2 (ja) * 2014-09-30 2020-08-12 株式会社エンビジョンＡｅｓｃエナジーデバイス リチウムイオン二次電池の製造方法
CN109464429B (zh) * 2018-12-13 2021-04-27 上海方予健康医药科技有限公司 一种吸入压力定量气雾剂药物组合物及其制备方法
CN110025578B (zh) * 2019-04-10 2021-06-15 深圳市新阳唯康科技有限公司 一种治疗哮喘类肺部疾病的共无定形粉末及其制备方法
WO2021195328A1 (en) * 2020-03-25 2021-09-30 Insmed Incorporated Pharmaceutical formulations of treprostinil prodrugs and methods of use thereof
FR3137830A1 (fr) * 2022-07-13 2024-01-19 Aptar France Sas Composition pharmaceutique comprenant du salbutamol

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5776434A (en) 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
ZA924164B (en) 1991-06-10 1993-02-24 Schering Corp Non-chlorofluorocarbon aerosol formulations
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
DK0616524T3 (da) 1991-12-12 1999-06-21 Glaxo Group Ltd Lægemidler
US5744123A (en) 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
ES2079210T3 (es) 1991-12-12 1996-01-01 Glaxo Group Ltd Formulacion farmaceutica de aerosol.
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
EP0617610B1 (en) 1991-12-18 1997-03-19 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
US5833950A (en) 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
ES2119219T5 (es) 1993-07-15 2011-05-11 Minnesota Mining And Manufacturing Company Cierres estancos para uso en un dispositivo para suministrar un aerosol.
EP0806940B1 (en) 1994-12-22 2003-04-09 AstraZeneca AB Aerosol drug formulations
US6013245A (en) 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
GB9626960D0 (en) 1996-12-27 1997-02-12 Glaxo Group Ltd Valve for aerosol container
AU718967B2 (en) * 1997-02-05 2000-05-04 Jagotec Ag Medical aerosol formulations
US5891420A (en) 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US5891419A (en) 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
JP3610426B2 (ja) 1998-06-04 2005-01-12 東京エレクトロン株式会社 基板姿勢制御装置
JP4570251B2 (ja) * 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
AU7026800A (en) 1999-09-11 2001-04-17 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
ES2238334T3 (es) * 1999-12-24 2005-09-01 Glaxo Group Limited Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
US6540983B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6540982B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6464959B1 (en) 2000-05-01 2002-10-15 Aeropharm Technology Incorporated Non-aqueous aerosol suspension comprising troglitazone, a fluid propellant, and an amino acid stabilizer
US6548049B1 (en) 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6447750B1 (en) 2000-05-01 2002-09-10 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6532684B1 (en) * 2000-10-12 2003-03-18 General Electric Company System for cleaning pressurized containers
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
EP3384931B1 (en) 2002-03-01 2019-07-24 Chiesi Farmaceutici S.p.A. Formoterol superfine formulation
SE0203376D0 (sv) * 2002-11-15 2002-11-15 Astrazeneca Ab New process
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
CN103462894A (zh) * 2005-03-16 2013-12-25 霍尼韦尔国际公司 药物递送制剂、装置和方法
CN101384248A (zh) * 2006-02-09 2009-03-11 贝林格尔英格海姆法玛两合公司 用于具有二种或多种活性剂以及至少一种表面活性剂的气雾剂的药物制剂
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
TWI495466B (zh) * 2010-09-23 2015-08-11 Intech Biopharm Ltd 用於氣喘之吸入性複方組合物
CN102416179B (zh) * 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物

Also Published As

Publication number Publication date
AU2012300082A1 (en) 2014-03-06
JP2014527056A (ja) 2014-10-09
WO2013026269A1 (zh) 2013-02-28
CN102670505B (zh) 2017-05-24
CA2845258C (en) 2016-05-10
SG2014011597A (en) 2014-03-28
KR20140042898A (ko) 2014-04-07
TW201238591A (en) 2012-10-01
EP2749275A4 (en) 2015-08-19
RU2014104996A (ru) 2015-09-27
EP2749275A1 (en) 2014-07-02
TWI399202B (zh) 2013-06-21
RU2582218C2 (ru) 2016-04-20
CA2845258A1 (en) 2013-02-28
NZ621362A (en) 2015-08-28
AU2012300082B2 (en) 2016-05-19
JP5938476B2 (ja) 2016-06-22
CN102670505A (zh) 2012-09-19

Similar Documents

Publication Publication Date Title
EP3111926B1 (en) Compositions, methods & systems for respiratory delivery of two or more active agents
US8324266B2 (en) Compositions, methods and systems for respiratory delivery of two or more active agents
US20150150787A1 (en) Compositions, methods & systems for respiratory delivery of three or more active agents
KR101586273B1 (ko) 호흡기 질환 치료용 정량분무식 흡입제의 제조 방법
JP2023540171A (ja) 吸入投与のための併用療法
US9241904B1 (en) Method for preparing metered dose sprayed inhaler for treating respiratory disease
AU2015201037B2 (en) Respiratory delivery of active agents
NZ621362B2 (en) Method for preparing metered dose sprayed inhaler for treating respiratory disease
HK1176550A (en) The preparation for formulation composition and manufacturing processes of metered does inhalers treated respiratory diseases
HK1176550B (en) The preparation for formulation composition and manufacturing processes of metered does inhalers treated respiratory diseases
CN105106200A (zh) 用于呼吸递送两种或多种活性剂的组合物、方法和系统
HK1228796B (en) Compositions, methods & systems for respiratory delivery of two or more active agents
HK1228796A1 (en) Compositions, methods & systems for respiratory delivery of two or more active agents
HK1228796A (en) Compositions, methods & systems for respiratory delivery of two or more active agents
HK1218867B (zh) 活性剂的呼吸递送
HK1169307B (en) Respiratory delivery of active agents

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20181231

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200113

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200113